Evidence map›Paper›PMID 40913733›Full record

ArticleBreast cancer research and treatment2025

Clinicopathologic features and contralateral breast cancer risk in BRCA1/2 pathogenic variant carriers: a multicenter registry study of Japanese women.

Kanae Taruno, Hiroki Den, Mieko Takeuchi, Mayuko Inuzuka, Masami Arai, Seigo Nakamura, Takanori Ishida, Registration Committee of the Japanese HBOC consortium

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kanae TarunoDivision of Breast Surgical Oncology, Department of Surgery, Showa Medical University School of Medicine, Tokyo, Japan. ktaruno@med.showa-u.ac.jp.ORCID http://orcid.org/0000-0002-7754-1548
Hiroki DenDepartment of Hygiene, Public Health, and Preventative Medicine, Showa Medical University School of Medicine, Tokyo, Japan.
Mieko TakeuchiDivision of Breast Surgical Oncology, Department of Surgery, Showa Medical University School of Medicine, Tokyo, Japan.
Mayuko InuzukaDivision of Breast Surgical Oncology, Department of Surgery, Showa Medical University School of Medicine, Tokyo, Japan.
Masami AraiDepartment of Clinical Genetics, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
Seigo NakamuraDivision of Breast Surgical Oncology, Department of Surgery, Showa Medical University School of Medicine, Tokyo, Japan.
Takanori IshidaDepartments of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, Miyagi, Japan.
Registration Committee of the Japanese HBOC consortium

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis large-scale study presents the clinicopathological characteristics and cumulative incidence of contralateral breast cancer (CBC) in Japanese BRCA1/2 pathogenic variant carriers, including cases diagnosed after the implementation of national insurance coverage.

methodsWe analyzed 2949 breast cancer cases from the registry database of the Japanese Organization of Hereditary Breast and Ovarian Cancer.

resultsBRCA1 carriers predominantly developed triple-negative breast cancer, whereas BRCA2 carriers more frequently developed luminal-type tumors, with a younger age of onset observed in BRCA1 carriers. No significant clinicopathological differences were found between the age groups. The cumulative incidence of CBC was 10.0% at five years and 29.0% at 10 years among BRCA1 carriers and 14.0% at five years and 19.0% at 10 years among BRCA2 carriers. CBC was observed in all age groups, including older patients. These findings highlight the importance of individualized decision-making in surgical planning and surveillance strategies.

conclusionsThis study included a broad age range of patients, reflecting real-world data following the expansion of insurance coverage in Japan. Further case studies and long-term follow-up are warranted. Our findings support the development of appropriate clinical care and preventive strategies for BRCA1/2 carriers in Japan.

Indexed as

BRCA1 ProteinBRCA2 ProteinBreast NeoplasmsAdultAgedEast Asian PeopleFemaleGenetic Predisposition to DiseaseHeterozygoteHumansIncidenceJapanMiddle AgedMutationRegistriesBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanBRCA1/2 pathogenic variantBreast cancerContralateral breast cancerCumulative incidenceJapanese registry

Identifiers

PMID40913733

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.